Literature DB >> 20596260

Multiple myeloma and bone disease: pathogenesis and current therapeutic approaches.

E C Papadopoulou1, S P Batzios, M Dimitriadou, V Perifanis, V Garipidou.   

Abstract

Multiple myeloma is a haematologic malignancy caused by clonal expansion of malignant plasma cells and associated with bone disease and hypercalcaemia. Myeloma cells are in close proximity to sites of active bone resorption and the interactions between those cells, osteoblasts and osteoclasts, are crucial not only for the bone distraction but for the proliferation of bone marrow cells as well. Recent studies have revealed that numerous regulating factors of osteoblast and osteoclast activity interfere with the pathogenesis of multiple myeloma's bone disease and that the understanding of the pathophysiological pathways involved is the first step towards discovering novel potential therapeutic approaches.

Entities:  

Keywords:  bone disease; hypercalcaemia; multiple myeloma; osteoblasts; osteoclasts

Year:  2010        PMID: 20596260      PMCID: PMC2895290     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  34 in total

1.  Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Authors:  W S Simonet; D L Lacey; C R Dunstan; M Kelley; M S Chang; R Lüthy; H Q Nguyen; S Wooden; L Bennett; T Boone; G Shimamoto; M DeRose; R Elliott; A Colombero; H L Tan; G Trail; J Sullivan; E Davy; N Bucay; L Renshaw-Gegg; T M Hughes; D Hill; W Pattison; P Campbell; S Sander; G Van; J Tarpley; P Derby; R Lee; W J Boyle
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

2.  IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma.

Authors:  Lori A Ehrlich; Ho Yeon Chung; Irene Ghobrial; Sun Jin Choi; Francesca Morandi; Simona Colla; Vittorio Rizzoli; G David Roodman; Nicola Giuliani
Journal:  Blood       Date:  2005-05-05       Impact factor: 22.113

3.  Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease.

Authors:  Babatunde O Oyajobi; Giovanni Franchin; Paul J Williams; Donna Pulkrabek; Anjana Gupta; Steve Munoz; Barry Grubbs; Ming Zhao; Di Chen; Barbara Sherry; Gregory R Mundy
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

4.  Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.

Authors:  Yoichi Tanaka; Masahiro Abe; Masahiro Hiasa; Asuka Oda; Hiroe Amou; Ayako Nakano; Kyoko Takeuchi; Kenichi Kitazoe; Shinsuke Kido; Daisuke Inoue; Keiji Moriyama; Toshihiro Hashimoto; Shuji Ozaki; Toshio Matsumoto
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

Review 5.  The pathogenesis of the bone disease of multiple myeloma.

Authors:  Claire M Edwards; Junling Zhuang; Gregory R Mundy
Journal:  Bone       Date:  2008-02-21       Impact factor: 4.398

6.  A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.

Authors:  Jean-Jacques Body; Philip Greipp; Robert E Coleman; Thierry Facon; Filip Geurs; Jean-Paul Fermand; Jean-Luc Harousseau; Allan Lipton; Xavier Mariette; Catherine D Williams; Arline Nakanishi; Donna Holloway; Steven W Martin; Colin R Dunstan; Pirow J Bekker
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

Review 7.  Targeting proteasomes as therapy in multiple myeloma.

Authors:  Dharminder Chauhan; Teru Hideshima; Kenneth C Anderson
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 8.  Multiple myeloma/hypercalcemia.

Authors:  Babatunde O Oyajobi
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 9.  Clinical development of anti-RANKL therapy.

Authors:  Edward M Schwarz; Christopher T Ritchlin
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

Review 10.  Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide.

Authors:  J B Bartlett; A Tozer; D Stirling; J B Zeldis
Journal:  Br J Cancer       Date:  2005-09-19       Impact factor: 7.640

View more
  8 in total

Review 1.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 2.  Bone disease in multiple myeloma: pathophysiology and management.

Authors:  Abdul Hameed; Jennifer J Brady; Paul Dowling; Martin Clynes; Peter O'Gorman
Journal:  Cancer Growth Metastasis       Date:  2014-08-10

Review 3.  New agents in the Treatment of Myeloma Bone Disease.

Authors:  Elizabeth S Ring; Michelle A Lawson; John A Snowden; Ingrid Jolley; Andrew D Chantry
Journal:  Calcif Tissue Int       Date:  2017-11-02       Impact factor: 4.333

4.  Clinical significance of trabecular bone score for prediction of pathologic fracture risk in patients with multiple myeloma.

Authors:  Eun Mi Lee; Bukyung Kim
Journal:  Osteoporos Sarcopenia       Date:  2018-06-11

5.  The osteoblastogenesis potential of adipose mesenchymal stem cells in myeloma patients who had received intensive therapy.

Authors:  Hsiu-Hsia Lin; Shiaw-Min Hwang; Shang-Ju Wu; Lee-Feng Hsu; Yi-Hua Liao; Yi-Shuan Sheen; Wen-Hui Chuang; Shang-Yi Huang
Journal:  PLoS One       Date:  2014-04-10       Impact factor: 3.240

6.  Effect of The Receptor Activator of Nuclear Factor кB and RANK Ligand on In Vitro Differentiation of Cord Blood CD133(+) Hematopoietic Stem Cells to Osteoclasts.

Authors:  Nasim Kalantari; Saeid Abroun; Masoud Soleimani; Saeid Kaviani; Mehdi Azad; Fatemeh Eskandari; Hossein Habibi
Journal:  Cell J       Date:  2016-08-24       Impact factor: 2.479

7.  I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma.

Authors:  Ning-Hong Guo; Ji-Fu Zheng; Fu-Ming Zi; Jing Cheng
Journal:  Biosci Rep       Date:  2019-05-14       Impact factor: 3.840

Review 8.  Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma.

Authors:  Sabah Akhtar; Tayyiba A Ali; Ammara Faiyaz; Omar S Khan; Syed Shadab Raza; Michal Kulinski; Halima El Omri; Ajaz A Bhat; Shahab Uddin
Journal:  Int J Mol Sci       Date:  2020-07-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.